
    
      This is a multicenter, randomized, open-label, single-dose, parallel-group study in subjects
      with clinically stable schizophrenia who are not currently taking risperidone. A total of
      approximately 48 subjects (16 per group) will be randomized to receive a single subcutaneous
      (SC) injection of RBP-7000 120 mg formulated with PLGH polymer of either 21 kilodaltons (kDa)
      (low MW group), 29 kDa of PLGH polymer (high MW group), or 26 kDa of PLGH polymer
      (intermediate MW group).
    
  